AIMS: The clinical definition and optimal treatment for @entity583 ( @entity583 ) type 2 (T2MI) are not well established. We assessed differences in presentation, treatment and outcomes of @entity1 with @entity583 (T1MI) and T2MI. METHODS: The data of @entity583 @entity1 enrolled in the AMIS Plus cohort with T2MI were compared with T1MI using propensity score matching. RESULTS: A total of 13829 @entity1 had T1MI and 1091 (7.3%) T2MI. @entity1 with T2MI were older, often female, with more risk factors and comorbidities, and less ST segment elevation. After matching for these differences (1091 per group), T2MI @entity1 less often presented with typical @entity662 but more frequently with @entity955 (15.6 vs. 4.9%; P<0.001) and @entity417 (33.5 vs. 23.3%; P<0.001) than @entity1 with T1MI. They less frequently received percutaneous coronary interventions (51.1 vs. 76.4%; P<0.001) and antiplatelet treatment. No differences were found for in-hospital (5.8 vs. 5.6%; OR 1.04; 95% confidence interval 0.72-1.49) and 1-year mortality (11.2 vs. 7.2%; P=0.38) between matched T2MI and T1MI @entity1 . CONCLUSION: @entity1 who suffered a T2MI had less typical symptoms, were less aggressively treated with anticoagulants, platelet inhibitors or percutaneous coronary intervention, but had similar complications and mortality to those with T1MI. @entity1 with T2MI are a heterogeneous group that requires further investigation to better define optimal therapeutic approaches.

Type 2 XXXX : incidence, presentation, treatment and outcome in routine clinical practice.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI', 'MI type 1']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']
